Administrative Supplements for NIAID Regional Biocontainment Laboratories (RBL)

NIAID 区域生物防护实验室 (RBL) 的行政补充

• 批准号: 10630718
• 负责人: Farhang Alem
• 金额: $ 403.99万
• 依托单位: GEORGE MASON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-23 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10630718
• 关键词: 2019-nCoV; Address; Administrative Supplement; Alphavirus; Animal Diseases; Animal Model; Animals; Applied Research; Award; Basic Science; Biochemistry; Biological Assay; Biology; Biomedical Engineering; Biomedical Research; Bunyaviridae; COVID-19 pandemic; Cells; Chikungunya virus; Clinical; Collaborations; Communicable Diseases; Community Health; Containment; Core Facility; Coronavirus; Development; Diagnostic; Ensure; Epidemic; Evaluation; FDA approved; Faculty; Family; Ferrets; Flaviviridae; Funding; Goals; Government; Histology; Image; Immunomodulators; In Vitro; Infection; Infectious Diseases Research; Infrastructure; Investments; Laboratories; Laboratory Research; Leadership; Methodology; Modernization; Molecular; National Institute of Allergy and Infectious Disease; Orthobunyavirus; PET/CT scan; Parents; Pathogenesis; Pathogenicity; Peer Review; Pharmaceutical Preparations; Population; Publishing; Rapid screening; Readiness; Reagent; Reporter; Research; Research Personnel; Rodent; Sampling; Security; Seeds; Sterilization; Students; System; Systems Analysis; Systems Biology; Talents; Technology; Therapeutic; Togaviridae; Universities; Vaccines; Venezuelan Equine Encephalitis Virus; Virus; Water; Western Equine Encephalitis Virus; advanced system; animal imaging; animal tissue; arm; base; cellular imaging; combat; extracellular vesicles; global health; human disease; imager; improved; in vivo; industry partner; innovation; instrument; instrumentation; member; multiple omics; neutralizing antibody; novel; operation; pandemic disease; pandemic preparedness; particle; pathogenic bacteria; pathogenic virus; pre-clinical; programs; recruit; research and development; sequencing platform; small molecule; technology development; therapeutic candidate; therapeutic development; tissue processing; transcriptomics; vaccine candidate; vaccine development

Project Summary/Abstract: The ongoing COVID pandemic has demonstrated the need for state-of-the-art facilities and infrastructure to improve our preparedness for subsequent epidemics and/or pandemics. George Mason University (GMU), leveraging the Regional Biocontainment Laboratory, designated as the Biomedical Research Laboratory (BRL), has established a biomedical research program with a strong emphasis on newly emerging and re- emerging viral and bacterial pathogens with the potential to cause severe human and animal diseases. The specific viral pathogen families of greatest pandemic concern currently investigated in the BRL are: Togaviridae, Bunyaviridae, Coronaviridae, and Flaviviridae. Several faculty members in five departments at GMU (Systems Biology, Biology, Bioengineering, Biochemistry, and Global and Community Health) as well as external collaborators conduct research on basic and applied research to include pathogenicity, infection mechanisms, and development of diagnostics, vaccines and therapeutics. The infectious disease portfolio at GMU was $8.8 million in FY21 and is expected to grow by at least 3X in the next five years. To realize this goal, GMU leadership is making aggressive, strategic investments in new faculty hires and seed funding, as well as creating broader access to the BRL. More than 244 peer-reviewed articles on infectious diseases research have been published by GMU investigators since 2010. The BRL staff is dedicated to supporting GMU faculty, students, and their collaborators to develop new translational solutions for pandemic preparedness. Research with translational promise includes 1) development of additional vaccine candidates that confer broad-spectrum protection against multiple strains of alphaviruses or coronaviruses, 2) evaluation of host-based therapeutics that have demonstrated in vitro broad- spectrum efficacy against alphaviruses (VEEV, EEEV, WEEV, CHIKV), bunyaviruses (RVFV) and coronaviruses (SARS-CoV-2) in rodent and nonrodent animal models including ferrets, and 3) development of new platform technologies including extracellular vesicle (EV)-based immunomodulators and reporter viruses that can facilitate rapid screening of clinical and nonclinical samples for neutralizing antibodies. Our high containment facility supported by a team of operations and technical staff, creates opportunities for a broad base of internal and external investigators to conduct in vitro and in vivo research and development on newly emerging and re-emerging viral and bacterial pathogens. GMU is requesting funds to supplement the funded G20 parent award, “Facility and Building System Upgrades Support for the Mason Biomedical Research Laboratory” to resolve additional specific instrumentation and facility gaps that will support the creation of a modern, comprehensive, agile and resilient preclinical biomedical research pipeline to address national and global pandemic preparedness.

项目摘要/摘要： 正在进行的共同大流行表明，需要最先进的设施和基础设施 改善我们对随后的发作和/或大流行的准备。乔治·梅森大学（GMU）， 利用区域生物疗养实验室，设计为生物医学研究实验室 （BRL）已经建立了一项生物医学研究计划 新兴的病毒和细菌病原体可能引起严重的人类和动物疾病。这 目前在BRL中研究的最大大流行关注的特定病毒病原体是： Togaviridae，Bunyaviridae，Coronaviridae和Flaviviridae。五个部门的几个教职员工 GMU（系统生物学，生物学，生物工程，生物化学以及全球和社区健康）以及 外部合作者对基础研究和应用研究进行研究以包括致病性，感染 诊断，疫苗和治疗的机制和开发。 GMU的传染病投资组合在21财年为880万美元，预计至少在3倍中增长3倍。 接下来的五年。为了实现这一目标，GMU领导正在对新教师进行积极进取的战略投资 雇用和种子资金，并为BRL创造更广泛的访问权限。超过244次同行评审的文章 自2010年以来，GMU研究人员发表了有关传染病研究的研究。 BRL员工致力于支持GMU教职员工，学生及其合作者开发新的 大流行准备的翻译解决方案。通过转化承诺的研究包括1） 开发其他候选疫苗的候选者，该疫苗会召集广泛保护的多种菌株 α病毒或冠状病毒，2）对基于宿主的治疗的评估，这些治疗表现为体外广泛 针对α病毒（VEEV，EEEV，WEEV，CHIKV），BUNYAVIRUS（RVFV）和 啮齿动物和非生产动物模型中的冠状病毒（SARS-COV-2），包括雪貂，3）发展 新的平台技术，包括基于细胞外蔬菜（EV）的免疫调节剂和记者病毒 这可以促进临床和非临床样品快速筛选中和抗体。 我们的高遏制设施由一支运营和技术人员支持，为 内部和外部调查人员的广泛基础在体外和体内研究与开发上进行了广泛的基础 新出现和重新出现病毒和细菌病原体。 GMU要求资金补充 资助G20父母奖，“设施和建筑系统升级对梅森生物医学的支持 研究实验室”，以解决将支持其他特定仪器和设施差距 创建现代，全面，敏捷和有弹性的临床前生物医学研究管道，以解决 国家和全球大流行准备。